Tel. +41 61 295 50 00info@baselarea. swiss
The University of Basel and the pharmaceutical company Vifor Pharma have agreed a public-private partnership. The world’s first research professorship for nanopharmaceutical and regulatory science is intended to strengthen the competitiveness of Switzerland as a location.
According to a media release, through their cooperation Vifor Pharma and the University of Basel want to ensure Switzerland’s ability to compete on the international stage in regard to pharma technologies of the future. To this end, Vifor Pharma Group is sponsoring two professorships in Nanopharmaceutical and Regulatory Science at the University of Basel. Both professorships will be based at the Department of Pharmaceutical Sciences and will receive 10 million Swiss francs in funding from Vifor Pharma Group over the coming ten years.
Nanomedicine can, for example, be used to develop treatments for overcoming specific cellular barriers in the human body. Therefore, it will play an ever more important role in the development of innovative new medications. At present, however, researchers are only just beginning to acquire the in-depth scientific insights needed for a fundamental understanding of the development of new products, their applications and especially the regulatory requirements across Europe and worldwide. There is also a lack of experts with the appropriate knowledge – and these experts are urgently needed in medical practice, including in Switzerland.
Switzerland is now to benefit from the cooperation between Vifor Pharma and the University of Basel in terms of its ability to compete internationally. There are also plans to establish and develop an internationally renowned Excellence Platform at the University of Basel for the development, authorization and application of nanopharmaceuticals, as well as the training of specialists in this area. Professor Andrea Schenker-Wicki, President of the University of Basel: “The crucial thing here is that we’re not only developing the scientific foundations, but also training the experts who will take this knowledge with them into industry and public authorities.” The aim is for the platform to seek out international partnerships and organize conferences, becoming a leading international center for nanopharmacy. “The field of nanopharmacy is growing quickly, and it’s important to secure a leading position in this innovative area of medicine with the help of qualified experts”, says Etienne Jornod, Executive Chairman of the Board of Directors at Vifor Pharma.